www.dailypolitical.com ·
Biote Q1 Earnings Call Highlights
Topic context
This topic has been covered 366624 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBiote's Q1 results were impacted by a voluntary recall of bioidentical hormone pellets, a specific product line. The recall reduced revenue and added costs, but the company expects recovery in H2. The mechanism is a single-company supply chain disruption (recall) affecting revenue and margins. No broader sector or commodity impact is evident.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Biote (BTMD) reported Q1 2026 revenue of $44.9M, down 8.3% YoY.
- Voluntary recall of bioidentical hormone pellet inventory reduced revenue by ~$1.7M and incurred $1.5M in additional costs.
- Procedure revenue fell 13.2% to $31.3M; dietary supplement revenue rose 19.1% to $11.0M.
- Company maintained 2026 guidance: revenue >$190M, adjusted EBITDA >$38M.
- Expects procedure revenue to return to growth in H2 2026.
Biote expects flat revenue in H2 as dietary supplement growth offsets procedure weakness post-recall.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- GLOBAL_HEALTHCAREshort
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
tickerreport.com
Roivant Sciences Nasdaqroiv Shares Gap Up on Strong Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com